ETF Home ETF List Shorted Stocks Home About

Portfolio Holdings Detail for ISIN IE00BYXG2H39
Stock Name / FundiShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerBTEC(USD) LSE
ETF TickerBTEK(GBP) LSE
ETF Ticker2B70(EUR) F
ETF Ticker2B70.DE(EUR) CXE
ETF TickerBTEC.LS(USD) CXE
ETF TickerBTEK.LS(GBP) CXE
ETF TickerBTEC.L(GBP) LSE
ETF TickerBTEK.L(GBP) LSE

Holdings detail for REGN

Stock NameRegeneron Pharmaceuticals Inc
TickerREGN(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS75886F1075
LEI549300RCBFWIRX3HYQ56

Show aggregate REGN holdings

News associated with REGN

Regeneron And Sanofi : CHMP Recommends EU Approval Of Dupixent For Chronic Spontaneous Urticaria
(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi announced that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion recommending the approval of Dupixent (dupilumab) in the European Union for treating c - 2025-09-22 02:12:20
Peek Under The Hood: JEPQ Has 10% Upside
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-09-08 08:26:56
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of “Moderate Buy” by Brokerages
Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) have been given an average recommendation of “Moderate Buy” by the twenty-six analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, six have issued a hold rating, sixteen have assigned a buy rating and three […] - 2025-08-26 02:16:48
LABU, INCY, UTHR, REGN: ETF Outflow Alert
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Direxion Daily S&P Biotech Bull 3x Shares (Symbol: LABU) where we have detected an approximate $67.3 million dollar outflow -- that's a 9.4% dec - 2025-08-20 12:04:03
Regeneron Pharmaceuticals (NASDAQ:REGN) versus Cadrenal Therapeutics (NASDAQ:CVKD) Head-To-Head Analysis
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) and Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability and earnings. Volatility and Risk Regeneron Pharmaceuticals has a beta […] - 2025-08-20 02:22:48
Truist Financial Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $812.00
Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price target reduced by Truist Financial from $940.00 to $812.00 in a research note published on Monday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. REGN has been the topic of several other reports. The Goldman Sachs Group dropped their price target on […] - 2025-08-14 03:00:52
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Position Raised by Blair William & Co. IL
Blair William & Co. IL lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 2.2% in the 1st quarter, Holdings Channel reports. The fund owned 1,282 shares of the biopharmaceutical company’s stock after buying an additional 27 shares during the period. Blair William & Co. IL’s holdings in Regeneron Pharmaceuticals were worth […] - 2025-08-11 06:26:50
Harbour Investments Inc. Sells 32 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Harbour Investments Inc. reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 7.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 403 shares of the biopharmaceutical company’s stock after selling 32 shares during the quarter. Harbour Investments Inc.’s holdings in […] - 2025-08-07 09:40:47
We Did The Math SPYX Can Go To $58
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-08-07 08:58:54
409 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Purchased by Arkadios Wealth Advisors
Arkadios Wealth Advisors purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 409 shares of the biopharmaceutical company’s stock, valued at approximately $259,000. Several other institutional investors and hedge funds also […] - 2025-08-07 05:38:53
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, BMO Capital Markets Analyst Says
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price target upped by stock analysts at BMO Capital Markets from $600.00 to $640.00 in a research report issued on Monday,Benzinga reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price target indicates a potential upside of 12.30% from […] - 2025-08-06 03:12:48
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives $828.86 Consensus Target Price from Brokerages
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) has been given a consensus rating of “Moderate Buy” by the twenty-four ratings firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, fifteen have assigned a buy recommendation and two […] - 2025-08-04 02:59:01
Stocks Slump on Tariffs and Weak US Job Growth
The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 19:31:54
Stocks Slump on Tariffs and Weak US Job Growth
The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 14:40:40
Stocks Slump on Tariffs and Weak US Job Growth
The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 14:35:36
Stocks Slump on Tariffs and Weak US Job Growth
The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 14:02:25
Nasdaq 100 Movers: MRVL, REGN
In early trading on Friday, shares of Regeneron Pharmaceuticals, topped the list of the day's best performing components of the Nasdaq 100 index, trading up 3.6%. Year to date, Regeneron Pharmaceuticals, has lost about 20.7% of its value. And the worst performing Nasdaq 100 co - 2025-08-01 11:30:09
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Choreo LLC
Choreo LLC boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 0.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,746 shares of the biopharmaceutical company’s stock after acquiring an additional 32 shares during the period. Choreo LLC’s holdings in Regeneron Pharmaceuticals […] - 2025-07-24 07:22:56
Crestwood Advisors Group LLC Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Crestwood Advisors Group LLC increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 5.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 467 shares of the biopharmaceutical company’s stock after purchasing an additional 25 shares during the quarter. Crestwood Advisors Group […] - 2025-07-24 05:47:12
Kestra Private Wealth Services LLC Has $1.31 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Kestra Private Wealth Services LLC grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 6.9% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,058 shares of the biopharmaceutical company’s stock after buying an additional 132 shares during the quarter. […] - 2025-07-23 07:50:58
Larson Financial Group LLC Has $34,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Larson Financial Group LLC lessened its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 34.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 53 shares of the biopharmaceutical company’s stock after selling 28 shares during the quarter. Larson […] - 2025-07-23 06:30:53
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Alps Advisors Inc.
Alps Advisors Inc. raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 71.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 530 shares of the biopharmaceutical company’s stock after purchasing an additional 220 shares during the quarter. Alps Advisors Inc.’s […] - 2025-07-17 05:50:54
Stratos Wealth Partners LTD. Sells 115 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Stratos Wealth Partners LTD. trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 18.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 506 shares of the biopharmaceutical company’s stock after selling 115 shares during the period. Stratos Wealth Partners […] - 2025-07-16 04:58:54
Allworth Financial LP Reduces Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Allworth Financial LP trimmed its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 14.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 821 shares of the biopharmaceutical company’s stock after selling 137 shares during the period. Allworth Financial […] - 2025-07-15 08:20:00
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $584.00
Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price target increased by UBS Group from $560.00 to $584.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock. Several other research analysts also recently commented on REGN. BMO Capital Markets reduced their price objective on Regeneron […] - 2025-07-14 03:30:48
Brown Advisory Inc. Reduces Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Brown Advisory Inc. lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 5.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,269 shares of the biopharmaceutical company’s stock after selling 247 shares during the quarter. Brown Advisory Inc.’s […] - 2025-07-13 05:54:54
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Cut by D.A. Davidson & CO.
D.A. Davidson & CO. reduced its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 2.8% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 732 shares of the biopharmaceutical company’s stock after selling 21 shares during the quarter. D.A. […] - 2025-07-11 05:32:52
Brokerages Set Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) PT at $813.57
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) has received an average recommendation of “Moderate Buy” from the twenty-five ratings firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating, fifteen have assigned a buy rating and three have issued […] - 2025-07-10 03:07:00
DAVENPORT & Co LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
DAVENPORT & Co LLC purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 427 shares of the biopharmaceutical company’s stock, valued at approximately $271,000. A number of other institutional […] - 2025-07-09 05:11:22
Bessemer Group Inc. Sells 3,860 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Bessemer Group Inc. decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 76.0% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,218 shares of the biopharmaceutical company’s stock after selling 3,860 shares during the period. Bessemer Group […] - 2025-07-01 05:46:52

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) REGN holdings

DateNumber of REGN Shares HeldBase Market Value of REGN SharesLocal Market Value of REGN SharesChange in REGN Shares HeldChange in REGN Base ValueCurrent Price per REGN Share HeldPrevious Price per REGN Share Held
2025-12-24 (Wednesday)68,723USD 53,858,902REGN holding decreased by -100336USD 53,858,9020USD -100,336 USD 783.71 USD 785.17
2025-12-23 (Tuesday)68,723REGN holding decreased by -1932USD 53,959,238REGN holding decreased by -1106443USD 53,959,238-1,932USD -1,106,443 USD 785.17 USD 779.36
2025-12-22 (Monday)70,655USD 55,065,681REGN holding increased by 805467USD 55,065,6810USD 805,467 USD 779.36 USD 767.96
2025-12-19 (Friday)70,655REGN holding decreased by -5708USD 54,260,214REGN holding decreased by -2913528USD 54,260,214-5,708USD -2,913,528 USD 767.96 USD 748.71
2025-12-18 (Thursday)76,363USD 57,173,742REGN holding decreased by -82472USD 57,173,7420USD -82,472 USD 748.71 USD 749.79
2025-12-17 (Wednesday)76,363REGN holding decreased by -870USD 57,256,214REGN holding decreased by -387408USD 57,256,214-870USD -387,408 USD 749.79 USD 746.36
2025-12-16 (Tuesday)77,233REGN holding decreased by -174USD 57,643,622REGN holding decreased by -614434USD 57,643,622-174USD -614,434 USD 746.36 USD 752.62
2025-12-15 (Monday)77,407REGN holding increased by 348USD 58,258,056REGN holding increased by 1134990USD 58,258,056348USD 1,134,990 USD 752.62 USD 741.29
2025-12-12 (Friday)77,059USD 57,123,066REGN holding decreased by -424595USD 57,123,0660USD -424,595 USD 741.29 USD 746.8
2025-12-11 (Thursday)77,059REGN holding increased by 1046USD 57,547,661REGN holding increased by 2346260USD 57,547,6611,046USD 2,346,260 USD 746.8 USD 726.21
2025-12-10 (Wednesday)76,013USD 55,201,401REGN holding increased by 2556317USD 55,201,4010USD 2,556,317 USD 726.21 USD 692.58
2025-12-09 (Tuesday)76,013USD 52,645,084REGN holding decreased by -811818USD 52,645,0840USD -811,818 USD 692.58 USD 703.26
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of REGN by Blackrock for IE00BYXG2H39

Show aggregate share trades of REGN

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-12-23SELL-1,932792.750777.000 778.575USD -1,504,207 650.89 Loss of -246,691 on sale
2025-12-19SELL-5,708773.850748.180 750.747USD -4,285,264 649.83 Loss of -576,011 on sale
2025-12-17SELL-870751.990743.330 744.196USD -647,451 648.97 Loss of -82,844 on sale
2025-12-16SELL-174757.350734.720 736.983USD -128,235 648.55 Loss of -15,387 on sale
2025-12-15BUY348756.660746.375 747.403USD 260,096 648.10
2025-12-11BUY1,046753.565726.455 729.166USD 762,708 647.25
2025-12-04BUY3,440735.000721.220 722.598USD 2,485,737 645.78
2025-12-03BUY111744.225720.140 722.549USD 80,203 645.42
2025-12-02BUY2,580747.000731.000 732.600USD 1,890,108 644.99
2025-11-28BUY172788.980779.500 780.448USD 134,237 643.88
2025-11-26BUY516790.980777.000 778.398USD 401,653 642.58
2025-11-26BUY516790.980777.000 778.398USD 401,653 642.58
2025-11-25BUY860790.570760.700 763.687USD 656,771 641.91
2025-11-24BUY172773.130756.640 758.289USD 130,426 641.35
2025-11-20SELL-688753.510720.020 723.369USD -497,678 640.36 Loss of -57,112 on sale
2025-11-19BUY172727.810702.630 705.148USD 121,285 640.06
2025-11-18BUY1,032727.970699.220 702.095USD 724,562 639.66
2025-11-17BUY344711.880692.290 694.249USD 238,822 639.35
2025-11-14BUY172699.270686.000 687.327USD 118,220 639.09
2025-11-12BUY172690.780672.670 674.481USD 116,011 638.61
2025-11-10BUY171665.990653.190 654.470USD 111,914 638.35
2025-11-06BUY171657.000641.260 642.834USD 109,925 638.21
2025-11-04BUY172646.221625.140 627.248USD 107,887 638.24
2025-10-30BUY860664.000645.000 646.900USD 556,334 638.07
2025-10-29BUY494652.910659.980 659.273USD 325,681 637.99
2025-10-22SELL-684584.740588.710 588.313USD -402,406 639.10 Profit of 34,738 on sale
2025-10-20BUY342576.770582.650 582.062USD 199,065 639.75
2025-10-17BUY855578.050579.040 578.941USD 494,995 640.07
2025-10-15BUY1,368576.420584.870 584.025USD 798,946 640.41
2025-10-03BUY1,190600.000618.010 616.209USD 733,289 641.00
2025-10-02BUY170600.000605.410 604.869USD 102,828 641.22
2025-09-30BUY340562.270574.040 572.863USD 194,773 641.88
2025-09-26BUY340563.900564.610 564.539USD 191,943 642.77
2025-09-25BUY340555.510579.000 576.651USD 196,061 643.25
2025-09-24SELL-4,129576.980577.980 577.880USD -2,386,066 643.63 Profit of 271,467 on sale
2025-09-18BUY181598.710600.000 599.871USD 108,577 643.88
2025-09-17BUY546585.500587.670 587.453USD 320,749 644.21
2025-09-11SELL-182568.200570.760 570.504USD -103,832 645.05 Profit of 13,567 on sale
2025-09-10BUY364555.830560.000 559.583USD 203,688 645.56
2025-09-05SELL-182573.380577.750 577.313USD -105,071 647.02 Profit of 12,687 on sale
2025-08-20SELL-728591.010596.920 596.329USD -434,128 648.05 Profit of 37,651 on sale
2025-08-18BUY364573.910585.000 583.891USD 212,536 648.96
2025-07-30BUY837554.580563.590 562.689USD 470,971 651.84
2025-07-17SELL-364550.000554.480 554.032USD -201,668 657.47 Profit of 37,652 on sale
2025-07-16BUY613547.930558.350 557.308USD 341,630 658.20
2025-07-11SELL-1,440567.740568.460 568.388USD -818,479 660.16 Profit of 132,157 on sale
2025-07-07BUY540538.110547.590 546.642USD 295,187 663.26
2025-07-02BUY9,900547.740551.500 551.124USD 5,456,128 664.90
2025-06-20BUY333509.720521.310 520.151USD 173,210 666.01
2025-06-13BUY95529.240529.550 529.519USD 50,304 671.50
2025-06-11BUY356518.600528.370 527.393USD 187,752 673.78
2025-06-10BUY356523.530529.990 529.344USD 188,446 674.92
2025-06-04SELL-178484.930499.900 498.403USD -88,716 680.55 Profit of 32,422 on sale
2025-04-23BUY178587.850603.770 602.178USD 107,188 712.12
2025-04-10SELL-1,424546.390571.990 569.430USD -810,868 727.37 Profit of 224,907 on sale
2025-04-08SELL-178556.810586.030 583.108USD -103,793 731.06 Profit of 26,336 on sale
2025-04-07SELL-178572.780591.540 589.664USD -104,960 732.90 Profit of 25,497 on sale
2025-04-04SELL-890573.450612.990 609.036USD -542,042 734.78 Profit of 111,911 on sale
2025-04-01BUY1,534617.000641.240 638.816USD 979,944 737.51
2025-03-31SELL-528634.230640.720 640.071USD -337,957 738.77 Profit of 52,115 on sale
2025-03-21BUY1,950658.480661.000 660.748USD 1,288,459 746.22
2025-03-14SELL-2,704666.870686.980 684.969USD -1,852,156 751.65 Profit of 180,307 on sale
2025-03-07SELL-338707.510729.750 727.526USD -245,904 754.95 Profit of 9,269 on sale
2025-03-04SELL-169675.490697.460 695.263USD -117,499 758.18 Profit of 10,633 on sale
2025-02-25BUY338723.470739.000 737.447USD 249,257 762.91
2025-02-19SELL-169685.660688.670 688.369USD -116,334 767.66 Profit of 13,400 on sale
2025-02-13BUY507674.270677.690 677.348USD 343,415 775.04
2025-02-12BUY169663.860670.980 670.268USD 113,275 777.31
2025-02-11BUY676665.460680.790 679.257USD 459,178 779.64
2025-01-02BUY82715.190726.810 725.648USD 59,503 815.28
2024-12-30BUY14,577702.590708.970 708.332USD 10,325,355 818.70
2024-11-18SELL-1,800762.000762.700 762.630USD -1,372,734 883.97 Profit of 218,410 on sale
2024-11-08SELL-120828.420830.730 830.499USD -99,660 892.43 Profit of 7,432 on sale
2024-10-30BUY63922.790935.860 934.553USD 58,877 941.44
2024-10-21SELL-119968.500991.240 988.966USD -117,687 0.00 Loss of -117,687 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of REGN

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19208,6591,635312,81266.7%
2025-09-18236,4853,679387,51961.0%
2025-09-17229,191716370,89561.8%
2025-09-16173,632584271,02064.1%
2025-09-15204,491251334,49661.1%
2025-09-12117,50433222,76052.7%
2025-09-11125,4783,137286,51643.8%
2025-09-10195,068481339,88557.4%
2025-09-09129,168994274,52047.1%
2025-09-08250,895396527,06247.6%
2025-09-05170,149290289,56658.8%
2025-09-04188,2272,103360,61952.2%
2025-09-03185,679344438,11142.4%
2025-09-02191,954138476,28840.3%
2025-08-29133,226685236,72656.3%
2025-08-28116,5602,177256,67545.4%
2025-08-27113,719465243,83646.6%
2025-08-26210,376450400,19952.6%
2025-08-25149,13068363,37741.0%
2025-08-22211,8223,244701,77030.2%
2025-08-21257,4923,416446,43957.7%
2025-08-20327,738572559,13358.6%
2025-08-19118,4722,191324,31136.5%
2025-08-18146,282388277,90952.6%
2025-08-15209,9233,375441,75247.5%
2025-08-14157,5693,623429,32736.7%
2025-08-13111,342233362,78630.7%
2025-08-12117,647171310,77537.9%
2025-08-11129,5132,676284,75745.5%
2025-08-08128,5591,038431,84129.8%
2025-08-07166,6481,560352,87747.2%
2025-08-06176,311624397,08944.4%
2025-08-05154,257115353,74443.6%
2025-08-04200,7581,913409,89749.0%
2025-08-01349,7753,745728,72048.0%
2025-07-31222,350476549,34440.5%
2025-07-30106,8391,689231,76146.1%
2025-07-29149,359276292,66751.0%
2025-07-28103,6871,380245,28742.3%
2025-07-25103,783556259,06940.1%
2025-07-24156,9742,397291,67753.8%
2025-07-23168,7341,708355,37247.5%
2025-07-22116,324617304,88038.2%
2025-07-2198,482900250,10739.4%
2025-07-18183,1741,051391,90946.7%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Copyright Market Footprint Ltd. Privacy Policy